Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 7OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Tumor-Agnostic 2Plasma cell 1Lymphoid 1Gynecologic 1Genitourinary 1

Conditions

Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Oxaliplatin 1004Fluorouracil 800Capecitabine 764Gemcitabine 650Leucovorin 559Irinotecan 537Bevacizumab 513Radiotherapy 460Cisplatin 440Drug Therapy 298Cetuximab 280Surgical Procedures, Operative 229Paclitaxel 228S 1 (combination) 217pembrolizumab 205Docetaxel 199130-nm albumin-bound paclitaxel 196Nivolumab 193sintilimab 191Radiosurgery 190lenvatinib 180Folfox protocol 179Sorafenib 178Albumin-Bound Paclitaxel 173apatinib 170tislelizumab 161camrelizumab 160Neoadjuvant Therapy 158Blood Specimen Collection 154durvalumab 148

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × futibatinib × Gastrointestinal × Clear all
NCT05615818 2026-05-19

SAFIR-ABC10

UNICANCER

Phase 3 Recruiting
800 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT07594548 2026-05-18

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Northwestern University

Phase 1 Not yet recruiting
18 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

NCT04828486 2025-11-18

Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer

Mayo Clinic

Phase 2 Completed
14 enrolled 13 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡